Douglas Min, MD
Allergy & Immunology · Dallas, TXNPI 1316927809
Payments from drug & device makers
Across 455 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$2K
- GSK$1K
- Sanofi$706
- Takeda Pharmaceuticals U.S.A., Inc.$648
- Kaleo, Inc.$573
- plus $3K from 30 others
What the payments were for
- Food & beverage$10,37599%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 67 | $2,058 |
| AstraZeneca | 86 | $1,725 |
| GSK | 80 | $1,452 |
| Sanofi | 25 | $706 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $648 |
| Kaleo, Inc. | 33 | $573 |
| Sanofi-aventis U.S. LLC | 13 | $331 |
| Covis Pharma GmbH | 17 | $325 |
| Optinose US, Inc. | 11 | $309 |
| Boehringer Ingelheim | 15 | $300 |
| Novartis | 9 | $286 |
| Alk-abello, Inc | 11 | $207 |
| Regeneron | 2 | $204 |
| Pfizer | 5 | $193 |
| Amgen | 8 | $145 |
| Grifols USA, LLC | 6 | $116 |
| Teva Pharmaceuticals USA, Inc. | 5 | $94 |
| CSL Behring | 4 | $88 |
| Integra Lifesciences Corporation | 2 | $83 |
| Octapharma USA, Inc. | 3 | $70 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $68 |
| Phadia US Inc. | 3 | $60 |
| Hospira, Inc. | 3 | $54 |
| LEO Pharma Inc. | 2 | $51 |
| Galderma Laboratories, L.p. | 2 | $39 |
| Blueprint Medicines Corporation | 2 | $38 |
| GC Biopharma USA, Inc. | 1 | $30 |
| Electromed, Inc. | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Biocryst US Sales Co., LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,448 in reported general payments places this provider in the 60th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 24 | $89,518 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $35,137 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $33,438 |
| Spiriva RespimatTiotropium Bromide | 25 | $18,347 |
| Qvar RedihalerBeclomethasone Dipropionate | 18 | $9,196 |
| Arnuity ElliptaFluticasone Furoate | 23 | $8,193 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $6,749 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,259 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,412 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,203 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $4,009 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 22 | $3,863 |
| Ipratropium Bromide | 77 | $3,021 |
| Epinephrine | 18 | $2,770 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,452 | $76,768122 claims |
| Boehringer IngelheimSpiriva Respimat | $300 | $18,34725 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $94 | $9,19618 claims |
| AstraZenecaSymbicort | $1,725 | $6,25922 claims |
| Hikma Pharmaceuticals USAEpinephrine | $23 | $2,77018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Barbara BaxterDallas$2.5M
- Richard WassermanDallas$1.9M
- Elliot GinchanskyDallas$477K
- Matthew FeldmanDallas$410K
- Lara GrossDallas$171K
- Anil NandaDallas$86K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.